NYSE · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP
Electromed, Inc. ELMD
16 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 73.8M
Revenue, FY2025 · full 16-year series below
Revenue $M
Net income $M
FY2025 · Revenue 73.8 · Net income 11.3
Compound annual growth
+15.4%
+15.6%
+12.4%
+9.5%
+52.8%
+36.8%
+17.7%
+17.1%
+53.4%
+36.9%
+17.0%
+16.6%
+168.2%
+21.3%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +15.6% a year over five years — but profit grew faster: net income at +36.8%, earnings per share at +36.9%.
The share count fell from 0.01B to 0.01B — the buyback concentrates the same profit into fewer slices.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
15 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 18.8% · Net 15.3%
ROE
FY2025 · ROE 23.3%
Each USD of equity produced 23 cents of profit this year.
The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 |
| EBITDA $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 |
| Net income $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 |
| Free cash flow $B | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 |
| EPS, diluted $ | 1.30 | 0.85 | 0.58 | 0.36 | 0.26 | 0.27 | 0.47 | 0.23 | 0.21 | 0.26 | 0.27 | 0.13 | −0.16 | −0.16 | 0.02 | 0.13 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 23.3 | 17.2 | 12.5 | 8.8 | 6.9 | 7.5 | 14.9 | 8.2 | 8.6 | 12.3 | 14.6 | 8.2 | −9.7 | −9.2 | 1.3 | 7.2 |
| Shares out B | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 80 reconciliationsAUDITED
Reconciled in 16 of 19 fiscal years. 15 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNYSE
Incorporated inMinnesota
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2010